(Q34223767)

English

Effects of glatiramer acetate on relapse rate and accumulated disability in multiple sclerosis: meta-analysis of three double-blind, randomized, placebo-controlled clinical trials.

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12926839%20AND%20SRC:MED&resulttype=core&format=json

7 November 2019

0 references

Effects of glatiramer acetate on relapse rate and accumulated disability in multiple sclerosis: meta-analysis of three double-blind, randomized, placebo-controlled clinical trials (English)

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12926839%20AND%20SRC:MED&resulttype=core&format=json

7 November 2019

0 references

0 references

multiple sclerosis

0 references

0 references

Filippo Martinelli Boneschi

1

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12926839%20AND%20SRC:MED&resulttype=core&format=json

7 November 2019

Massimo Filippi

9

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12926839%20AND%20SRC:MED&resulttype=core&format=json

7 November 2019

author name string

Marco Rovaris

2

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12926839%20AND%20SRC:MED&resulttype=core&format=json

7 November 2019

Kenneth P Johnson

3

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12926839%20AND%20SRC:MED&resulttype=core&format=json

7 November 2019

Aaron Miller

4

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12926839%20AND%20SRC:MED&resulttype=core&format=json

7 November 2019

Jerry S Wolinsky

5

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12926839%20AND%20SRC:MED&resulttype=core&format=json

7 November 2019

David Ladkani

6

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12926839%20AND%20SRC:MED&resulttype=core&format=json

7 November 2019

Galia Shifroni

7

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12926839%20AND%20SRC:MED&resulttype=core&format=json

7 November 2019

Giancarlo Comi

8

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12926839%20AND%20SRC:MED&resulttype=core&format=json

7 November 2019

publication date

1 August 2003

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12926839%20AND%20SRC:MED&resulttype=core&format=json

7 November 2019

Multiple Sclerosis Journal

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12926839%20AND%20SRC:MED&resulttype=core&format=json

7 November 2019

9

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12926839%20AND%20SRC:MED&resulttype=core&format=json

7 November 2019

4

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12926839%20AND%20SRC:MED&resulttype=core&format=json

7 November 2019

349-355

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12926839%20AND%20SRC:MED&resulttype=core&format=json

7 November 2019

Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG)

1 reference

https://api.crossref.org/works/10.1191%2F1352458503MS932OA

21 January 2018

A pilot trial of Cop 1 in exacerbating-remitting multiple sclerosis

1 reference

https://api.crossref.org/works/10.1191%2F1352458503MS932OA

21 January 2018

Extended use of glatiramer acetate (Copaxone) is well tolerated and maintains its clinical effect on multiple sclerosis relapse rate and degree of disability. Copolymer 1 Multiple Sclerosis Study Group

1 reference

https://api.crossref.org/works/10.1191%2F1352458503MS932OA

21 January 2018

European/Canadian multicenter, double-blind, randomized, placebo-controlled study of the effects of glatiramer acetate on magnetic resonance imaging-measured disease activity and burden in patients with relapsing multiple sclerosis

1 reference

https://api.crossref.org/works/10.1191%2F1352458503MS932OA

21 January 2018

Interferon beta decreases T cell activation and interferon gamma production in multiple sclerosis

1 reference

https://api.crossref.org/works/10.1191%2F1352458503MS932OA

21 January 2018

Interferon beta induces interleukin-10 expression: relevance to multiple sclerosis.

1 reference

https://api.crossref.org/works/10.1191%2F1352458503MS932OA

21 January 2018

Interferon-alpha/beta inhibition of interleukin 12 and interferon-gamma production in vitro and endogenously during viral infection

1 reference

https://api.crossref.org/works/10.1191%2F1352458503MS932OA

21 January 2018

Cross-reactions and specificities of monoclonal antibodies against myelin basic protein and against the synthetic copolymer 1

1 reference

https://api.crossref.org/works/10.1191%2F1352458503MS932OA

21 January 2018

Synthetic copolymer 1 inhibits human T-cell lines specific for myelin basic protein

1 reference

https://api.crossref.org/works/10.1191%2F1352458503MS932OA

21 January 2018

Mechanisms of action of glatiramer acetate in multiple sclerosis

1 reference

https://api.crossref.org/works/10.1191%2F1352458503MS932OA

21 January 2018

Treatment of multiple sclerosis with copolymer-1 (Copaxone): implicating mechanisms of Th1 to Th2/Th3 immune-deviation.

1 reference

https://api.crossref.org/works/10.1191%2F1352458503MS932OA

21 January 2018

Mechanisms of action of interferons and glatiramer acetate in multiple sclerosis

1 reference

https://api.crossref.org/works/10.1191%2F1352458503MS932OA

21 January 2018

New diagnostic criteria for multiple sclerosis: guidelines for research protocols

1 reference

https://api.crossref.org/works/10.1191%2F1352458503MS932OA

21 January 2018

Defining the clinical course of multiple sclerosis: Results of an international survey

1 reference

https://api.crossref.org/works/10.1191%2F1352458503MS932OA

21 January 2018

Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS)

1 reference

https://api.crossref.org/works/10.1191%2F1352458503MS932OA

21 January 2018

Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group

1 reference

https://api.crossref.org/works/10.1191%2F1352458503MS932OA

21 January 2018

Correlations between monthly enhanced MRI lesion rate and changes in T2 lesion volume in multiple sclerosis.

1 reference

https://api.crossref.org/works/10.1191%2F1352458503MS932OA

21 January 2018

Predictive value of gadolinium-enhanced magnetic resonance imaging for relapse rate and changes in disability or impairment in multiple sclerosis: a meta-analysis. Gadolinium MRI Meta-analysis Group.

1 reference

https://api.crossref.org/works/10.1191%2F1352458503MS932OA

21 January 2018

The natural history of multiple sclerosis: a geographically based study. 3. Multivariate analysis of predictive factors and models of outcome.

1 reference

https://api.crossref.org/works/10.1191%2F1352458503MS932OA

21 January 2018

Sustained clinical benefits of glatiramer acetate in relapsing multiple sclerosis patients observed for 6 years. Copolymer 1 Multiple Sclerosis Study Group

1 reference

https://api.crossref.org/works/10.1191%2F1352458503MS932OA

21 January 2018

Randomised double-blind placebo-controlled study of interferon β-1a in relapsing/remitting multiple sclerosis

1 reference

https://api.crossref.org/works/10.1191%2F1352458503MS932OA

21 January 2018

Identifiers

10.1191/1352458503MS932OA

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12926839%20AND%20SRC:MED&resulttype=core&format=json

7 November 2019

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12926839%20AND%20SRC:MED&resulttype=core&format=json

7 November 2019

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q34223767&oldid=1603607870"